

1438971

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

SEC  
Mail Processing  
Section

OCT 07 2008

Washington, DC  
101

FORM D

NOTICE OF SALE OF SECURITIES  
PURSUANT TO REGULATION D,  
SECTION 4(6), AND/OR  
UNIFORM LIMITED OFFERING EXEMPTION



Name of Offering ([ ] check if this is an amendment and name has changed, and indicate change.)

**Slate Pharmaceuticals, Inc. Offering of Subordinated Secured Promissory Notes, Warrants to Purchase Shares and Series A Preferred Stock**

Filing Under (Check box(es) that apply): [ ] Rule 504 [ ] Rule 505 [X] Rule 506 [ ] Section 4(6) [ ] ULOE

Type of Filing: [x] New Filing [ ] Amendment

A. BASIC IDENTIFICATION DATA

PROCESSED

OCT 15 2008

1. Enter the information requested about the issuer

Name of Issuer ([ ] check if this is an amendment and name has changed, and indicate change.)

**Slate Pharmaceuticals, Inc.**

~~THOMSON REUTERS~~

Address of Executive Offices (Number and Street, City, State, Zip Code)

**318 Blackwell Street, Suite 240,  
Durham, North Carolina, 27701**

Telephone Number (Including Area Code)

**(919) 682-8800, Ext. 150**

Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number (Including Area Code)  
(if different from Executive Offices)

Brief Description of Business

**Pharmaceuticals and drug delivery.**

Type of Business Organization

[X] corporation [ ] limited partnership, already formed [ ] other (please specify):  
[ ] business trust [ ] limited partnership, to be formed

Actual or Estimated Date of Incorporation or Organization: Month Year  
[0][5] [0][7] [X] Actual [ ] Estimated

Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:  
CN for Canada; FN for other foreign jurisdiction) [D][E]

---

**A. BASIC IDENTIFICATION DATA**

---

2. Enter the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**Robert S. Whitehead**

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**W. Robert Dahl**

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**Trygve Mikkelsen**

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**Douglas Eckert**

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**Michael Ford**

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**Richard DeSchutter**

---

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

**Tony Wild**

---

Business or Residence Address (Number and Street, City, State, Zip Code)

**c/o Slate Pharmaceuticals, Inc., 318 Blackwell Street, Suite 240, Durham, NC 27701**

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

---

Business or Residence Address (Number and Street, City, State, Zip Code)

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

---

Business or Residence Address (Number and Street, City, State, Zip Code)

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

---

Business or Residence Address (Number and Street, City, State, Zip Code)

---

Check Box(es) that Apply:     Promoter    Beneficial Owner    Executive Officer    Director    General and/or  
Managing Partner

---

Full Name (Last name first, if individual)

---

Business or Residence Address (Number and Street, City, State, Zip Code)

---

**B. INFORMATION ABOUT OFFERING**

1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?..... Yes No

Answer also in Appendix, Column 2, if filing under ULOE.

2. What is the minimum investment that will be accepted from any individual?..... **N/A**

3. Does the offering permit joint ownership of a single unit?..... Yes No

4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.

Full Name (Last name first, if individual) **N/A**

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers  
 (Check "All States" or check individual States)

All States

|      |      |      |      |      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|------|------|------|------|
| [AL] | [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL] | [IN] | [IA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [MT] | [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI] | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] |

Full Name (Last name first, if individual) **N/A**

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers  
 (Check "All States" or check individual States)

All States

|      |      |      |      |      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|------|------|------|------|
| [AL] | [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL] | [IN] | [IA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [MT] | [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI] | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] |

Full Name (Last name first, if individual) **N/A**

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers  
 (Check "All States" or check individual States)

All States

|      |      |      |      |      |      |      |      |      |      |      |      |      |
|------|------|------|------|------|------|------|------|------|------|------|------|------|
| [AL] | [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL] | [IN] | [IA] | [KS] | [KY] | [LA] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [MT] | [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI] | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] |

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

**C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS**

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box  and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

| Type of Security                                  | Aggregate<br>Offering Price | Amount Already<br>Sold |
|---|-----------------------------|------------------------|
| Debt .....  | \$ 750,000                  | \$ 749,997             |
| Equity .....                                      | \$1,000,000                 | \$1,000,000            |
| [ ] Common [X] Preferred                          |                             |                        |
| Convertible Securities (including warrants) ..... | \$ 250,000                  | \$ 249,999             |
| Partnership Interests .....                       | \$ 0                        | \$ 0                   |
| Other (Specify: _____) .....                      | \$ 0                        | \$ 0                   |
| <b>Total</b> .....                                | <b>\$2,000,000</b>          | <b>\$1,999,996</b>     |

Answer also in Appendix, Column 3, if filing under ULOE.

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."

|  | Number Investors | Aggregate<br>Dollar Amount<br>of Purchases |
|--|------------------|--|
| Accredited Investors .....                           | 23               | \$1,999,996                                |
| Non-accredited Investors .....                       | 0                | \$ 0                                       |
| <b>Total (for filings under Rule 504 only)</b> ..... | <b>N/A</b>       | <b>\$ N/A</b>                              |

Answer also in Appendix, Column 4, if filing under ULOE.

3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C-Question 1.

| Type of offering          | Type of Security | Dollar Amount<br>Sold |
|---------------------------|------------------|-----------------------|
| Rule 505 .....            | N/A              | \$ N/A                |
| <u>Regulation A</u> ..... | N/A              | \$ N/A                |
| Rule 504 .....            | N/A              | \$ N/A                |
| <b>Total</b> .....        | N/A              | <b>\$ N/A</b>         |

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

|  |              |
|--|--------------|
| Transfer Agent's Fees .....  | [ ] \$ 0     |
| Printing and Engraving Costs .....   | [ ] \$ 0     |
| Legal Fees .....   | [X] \$20,000 |
| Accounting Fees .....  | [X] \$ 2,000 |
| Engineering Fees .....   | [ ] \$ 0     |
| Sales Commissions (specify finders' fees separately) .....   | [ ] \$ 0     |
| Other Expenses (identify): title and liability insurance, surveys, appraisal, origination fee, closing costs, manager overhead, property maintenance costs, property taxes, wetland study, reserves and building removal costs and administrative fee..... | [ ] \$ 0     |
| <b>Total</b> .....   | [X] \$22,000 |

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." .....


\$1,978,000

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.

|   | Payments to<br>Officers,<br>Directors, &<br>Affiliates | Payments To<br>Others |
|---|--|-----------------------|
| Salaries and fees .....   | [] \$ _____  | [] \$ _____           |
| Purchase of real estate .....   | [] \$ _____  | [] \$ _____           |
| Purchase, rental or leasing and installation of machinery<br>and equipment .....  | [] \$ _____  | [] \$ _____           |
| Construction or leasing of plant buildings and facilities.....  | [] \$ _____  | [] \$ _____           |
| Acquisition of other businesses (including the value of<br>securities involved in this offering that may be used in<br>exchange for the assets or securities of another issuer<br>pursuant to a merger) ..... | [] \$ _____  | [] \$ _____           |
| Repayment of indebtedness .....   | [] \$ _____  | [] \$ _____           |
| Working capital .....   | [] \$ _____  | [X] \$1,978,000       |
| Other (specify): .....  | [] \$ _____  | [] \$ _____           |
| Column Totals .....   | [] \$ _____  | [X] \$1,978,000       |
| Total Payments Listed (column totals added) .....   |  | [X] \$1,978,000       |

**D. FEDERAL SIGNATURE**

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

|  |   |                 |
|--|---|-----------------|
| Issuer (Print or Type)<br><b>Slate Pharmaceuticals, Inc.</b> | Signature<br> | Date<br>10/6/08 |
| Name of Signer (Print or Type)<br><b>Robert S. Whitehead</b> | Title of Signer (Print or Type)<br><b>President</b>   |                 |

|   |
|---|
| <b>ATTENTION</b>  |
| <b>Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)</b> |

END